Technical Analysis for PSTV - Plus Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.84% | |
| Stochastic Buy Signal | Bullish | 0.84% | |
| Narrow Range Bar | Range Contraction | 0.84% | |
| Inside Day | Range Contraction | 0.84% | |
| Oversold Stochastic | Weakness | 0.84% | |
| Gapped Up | Strength | -3.23% | |
| Oversold Stochastic | Weakness | -3.23% | |
| NR7 | Range Contraction | 0.84% | |
| Narrow Range Bar | Range Contraction | 0.84% | |
| Lower Bollinger Band Walk | Weakness | 0.84% |
| Alert | Time |
|---|---|
| Gap Up Closed | 28 minutes ago |
| Gap Up Partially Closed | 28 minutes ago |
| Gapped Up (Partial) | about 3 hours ago |
| Up 2% | about 3 hours ago |
| Up 1% | about 3 hours ago |
Get a Trading Assistant
- Earnings date: 11/14/2024
Plus Therapeutics, Inc. Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Clinical Medicine Pharmaceutical Disease Drugs Ovarian Cancer Small Cell Lung Cancer Blastoma Glioblastoma Multiple Myeloma Sarcoma Stage Pharmaceutical Pegylation Breast And Ovarian Cancer Docetaxel Doxorubicin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.6702 |
| 52 Week Low | 1.145 |
| Average Volume | 86,537 |
| 200-Day Moving Average | 1.71 |
| 50-Day Moving Average | 1.39 |
| 20-Day Moving Average | 1.30 |
| 10-Day Moving Average | 1.24 |
| Average True Range | 0.10 |
| RSI (14) | 40.83 |
| ADX | 9.64 |
| +DI | 18.36 |
| -DI | 20.57 |
| Chandelier Exit (Long, 3 ATRs) | 1.18 |
| Chandelier Exit (Short, 3 ATRs) | 1.47 |
| Upper Bollinger Bands | 1.44 |
| Lower Bollinger Band | 1.15 |
| Percent B (%b) | 0.13 |
| BandWidth | 22.20 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.009 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.27 | ||||
| Resistance 3 (R3) | 1.27 | 1.25 | 1.25 | ||
| Resistance 2 (R2) | 1.25 | 1.23 | 1.25 | 1.25 | |
| Resistance 1 (R1) | 1.22 | 1.22 | 1.21 | 1.22 | 1.24 |
| Pivot Point | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
| Support 1 (S1) | 1.17 | 1.18 | 1.16 | 1.17 | 1.14 |
| Support 2 (S2) | 1.15 | 1.17 | 1.15 | 1.13 | |
| Support 3 (S3) | 1.12 | 1.15 | 1.13 | ||
| Support 4 (S4) | 1.12 |
